Όλο το DSpace

Πλοήγηση ανά Θέμα "hepatitis C"

Αποτελέσματα 1-20 από 23

    • Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: Report from a high level conference 

      Papatheodoridis G., Thomas H.C., Golna C., Bernardi M., Carballo M., Cornberg M., Dalekos G., Degertekin B., Dourakis S., Flisiak R., Goldberg D., Gore C., Goulis I., Hadziyannis S., Kalamitsis G., Kanavos P., Kautz A., Koskinas I., Leite B.R., Malliori M., Manolakopoulos S., Matičič M., Papaevangelou V., Pirona A., Prati D., Raptopoulou-Gigi M., Reic T., Robaeys G., Schatz E., Souliotis K., Tountas Y., Wiktor S., Wilson D., Yfantopoulos J., Hatzakis A. (2016)
      Summary In the WHO-EURO region, around 28 million people are currently living with chronic viral hepatitis, and 120 000 people die every year because of it. Lack of awareness and understanding combined with the social ...

    • The antiphospholipid syndrome and infection 

      Dalekos, G. N.; Zachou, K.; Liaskos, C. (2001)
      Infectious agents have been implicated in the induction of antiphospholipid (aPL) antibodies and the development of the antiphospholipid syndrome (APS). This review focuses on the types of aPL antibodies detected in ...

    • Autoantibodies and autoantigens associated with autoimmune hepatitis and viruses-induced autoimmune response: Significant tools in clinical practice and in the study of pathogenesis of autoimmune hepatic diseases 

      Dalekos, G. N. (2004)
      Autoimmune hepatitis (AIH) is a chronic necroinflammatory disease of the liver characterized by hypergamma-globulinemia, characteristic autoantibodies, association with HLA DR3 or DR4 and a favorable response to immunosuppressive ...

    • Autoantibodies to asialoglycoprotein receptor (ASGPR) in patients with autoimmune liver diseases 

      Villalta, D.; Mytilinaiou, M. G.; Elsner, M.; Hentschel, C.; Cuccato, J.; Somma, V.; Schierack, P.; Roggenbuck, D.; Bogdanos, D. P. (2015)
      Background: The liver asialoglycoprotein receptor (ASGPR) is the only organ-specific autoantigenic target in autoimmune hepatitis (AIH) patients and corresponding autoantibodies (Abs) have been suggested aiding in the ...

    • Blocking of interleukin-10 receptor - A novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus 

      Rigopoulou, E. I.; Abbott, W. G. H.; Haigh, P.; Naoumov, N. V. (2005)
      Chronic hepatitis C virus (HCV) infection is associated with weak CD4+ T-helper type 1 reactivity and enhanced interleukin-10 production to HCV antigens. Here we demonstrate in vitro that monoclonal antibody-induced blockade ...

    • Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece 

      Touloumi G., Kalpourtzi N., Papastamopoulos V., Paparizos V., Adamis G., Antoniadou A., Chini M., Karakosta A., Makrilakis K., Gavana M., Vantarakis A., Psichogiou M., Metallidis S., Sipsas N.V., Sambatakou H., Hadjichristodoulou C., Voulgari P.V., Chrysos G., Gogos C.A., Chlouverakis G., Tripsianis G., Alamanos Y., Stergiou G., Alexis B., Anna K., Nikos P., Georgia V., Klea K., Maria K., Xenia C., Alexis B., Magda G., Bettina H., Christos H., George R., Ilias N., Koustenis P., Stavros L., Ioannis I., Athanasios R., Stella I., Alexios S., Gikas A., Gogos H.A., Katsarou O., Lazanas M., Panagopoulos P., Paraskevis D., Psychogiou M., Papadopoulos A., Nitsotolis T., Xylomenos G., Marangos M.N., Kouramba A., Kontos A., Lioni A., Tsachouridou O., Kourkounti S., Ganitis A., Barbounakis E., AMACS and EMENO (2020)
      Background Although combined antiretroviral therapy has substantially improved the prognosis of people living with HIV (PLHIV), mortality remains higher compared to the general population, mainly due to higher prevalence ...

    • Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C 

      Gatselis, N. K.; Georgiadou, S. P.; Koukoulis, G. K.; Tassopoulos, N.; Zachou, K.; Liaskos, C.; Hatzakis, A.; Dalekos, G. N. (2006)
      Background: Development of organ- and non-organ-specific autoantibodies has been reported in hepatitis C virus patients treated with interferon-α plus/minus ribavirin. Aims: To address whether prevalence and the titre of ...

    • Cross-genotype-reactivity of the immunodominant HCVCD8 T-cell epitope NS3-1073 

      Fytili, P.; Dalekos, G. N.; Schlaphoff, V.; Suneetha, P. V.; Sarrazin, C.; Zauner, W.; Zachou, K.; Berg, T.; Manns, M. P.; Klade, C. S.; Cornberg, M.; Wedemeyer, H. (2008)
      The HCV-specific HLA-A2-restricted NS3(1073) epitope is one of the most frequently recognized epitopes in hepatitis C. NS3(1073)-specific T-cell responses are associated with clearance of acute HCV-infection. Therefore ...

    • Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: Is there a role in clinical practice? 

      de Mello R.A., Zhu J.-H., Iavelberg J., Potim A.H., Simonetti D., Júnior J.A.S., Castelo-Branco P., Pozza D.H., Tajima C.C., Tolia M., Antoniou G. (2020)
      [No abstract available]

    • Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016 

      Naghavi M., Abajobir A.A., Abbafati C., Abbas K.M., Abd-Allah F., Abera S.F., Aboyans V., Adetokunboh O., Ärnlöv J., Afshin A., Agrawal A., Kiadaliri A.A., Ahmadi A., Ahmed M.B., Aichour A.N., Aichour I., Aichour M.T.E., Aiyar S., Al-Eyadhy A., Alahdab F., Al-Aly Z., Alam K., Alam N., Alam T., Alene K.A., Ali S.D., Alizadeh-Navaei R., Alkaabi J.M., Alkerwi A., Alla F., Allebeck P., Allen C., Al-Raddadi R., Alsharif U., Altirkawi K.A., Alvis-Guzman N., Amare A.T., Amini E., Ammar W., Amoako Y.A., Anber N., Andersen H.H., Andrei C.L., Androudi S., Ansari H., Antonio C.A.T., Anwari P., Arora M., Artaman A., Aryal K.K., Asayesh H., Asgedom S.W., Atey T.M., Avila-Burgos L., Avokpaho E.F.G.A., Awasthi A., Quintanilla B.P.A., Béjot Y., Babalola T.K., Bacha U., Balakrishnan K., Barac A., Barboza M.A., Barker-Collo S.L., Barquera S., Barregard L., Barrero L.H., Baune B.T., Bedi N., Beghi E., Bekele B.B., Bell M.L., Bennett J.R., Bensenor I.M., Berhane A., Bernabé E., Betsu B.D., Beuran M., Bhatt S., Biadgilign S., Bienhof K., Bikbov B., Bisanzio D., Bourne R.R.A., Breitborde N.J.K., Bulto L.N.B., Bumgarner B.R., Butt Z.A., Cárdenas R., Cahuana-Hurtado L., Cameron E., Campuzano J.C., Car J., Carrero J.J., Carter A., Casey D.C., Castañeda-Orjuela C.A., Catalá-López F., Charlson F.J., Chibueze C.E., Chimed-Ochir O., Chisumpa V.H., Chitheer A.A., Christopher D.J., Ciobanu L.G., Cirillo M., Cohen A.J., Colombara D., Cooper C., Cowie B.C., Criqui M.H., Dandona L., Dandona R., Dargan P.I., Das Neves J., Davitoiu D.V., Davletov K., De Courten B., Degenhardt L., Deiparine S., Deribe K., Deribew A., Dey S., Dicker D., Ding E.L., Djalalinia S., Do H.P., Doku D.T., Douwes-Schultz D., Driscoll T.R., Dubey M., Duncan B.B., Echko M., El-Khatib Z.Z., Ellingsen C.L., Enayati A., Erskine H.E., Eskandarieh S., Esteghamati A., Ermakov S.P., Estep K., Sa Farinha C.S., Faro A., Farzadfar F., Feigin V.L., Fereshtehnejad S.-M., Fernandes J.C., Ferrari A.J., Feyissa T.R., Filip I., Finegold S., Fischer F., Fitzmaurice C., Flaxman A.D., Foigt N., Frank T., Fraser M., Fullman N., Fürst T., Furtado J.M., Gakidou E., Garcia-Basteiro A.L., Gebre T., Gebregergs G.B., Gebrehiwot T.T., Gebremichael D.Y., Geleijnse J.M., Genova-Maleras R., Gesesew H.A., Gething P.W., Gillum R.F., Ginawi I.A.M., Giref A.Z., Giroud M., Giussani G., Godwin W.W., Gold A.L., Goldberg E.M., Gona P.N., Gopalani S.V., Gouda H.N., Goulart A.C., Griswold M., Gupta P.C., Gupta R., Gupta T., Gupta V., Haagsma J.A., Hafezi-Nejad N., Hailu A.D., Hailu G.B., Hamadeh R.R., Hambisa M.T., Hamidi S., Hammami M., Hancock J., Handal A.J., Hankey G.J., Hao Y., Harb H.L., Hareri H.A., Hassanvand M.S., Havmoeller R., Hay S.I., He F., Hedayati M.T., Henry N.J., Heredia-Pi I.B., Herteliu C., Hoek H.W., Horino M., Horita N., Hosgood H.D., Hostiuc S., Hotez P.J., Hoy D.G., Huynh C., Iburg K.M., Ikeda C., Ileanu B.V., Irenso A.A., Irvine C.M.S., Jürisson M., Jacobsen K.H., Jahanmehr N., Jakovljevic M.B., Javanbakht M., Jayaraman S.P., Jeemon P., Jha V., John D., Johnson C.O., Johnson S.C., Jonas J.B., Kabir Z., Kadel R., Kahsay A., Kamal R., Karch A., Karimi S.M., Karimkhani C., Kasaeian A., Kassaw N.A., Kassebaum N.J., Katikireddi S.V., Kawakami N., Keiyoro P.N., Kemmer L., Kesavachandran C.N., Khader Y.S., Khan E.A., Khang Y.-H., Khoja A.T.A., Khosravi A., Khosravi M.H., Khubchandani J., Kieling C., Kievlan D., Kim D., Kim Y.J., Kimokoti R.W., Kinfu Y., Kissoon N., Kivimaki M., Knudsen A.K., Kopec J.A., Kosen S., Koul P.A., Koyanagi A., Defo B.K., Kulikof X.R., Kumar G.A., Kumar P., Kutz M., Kyu H.H., Lal D.K., Lalloo R., Lambert T.L.N., Lan Q., Lansingh V.C., Larsson A., Lee P.H., Leigh J., Leung J., Levi M., Li Y., Kappe D.L., Liang X., Liben M.L., Lim S.S., Liu A., Liu P.Y., Liu Y., Lodha R., Logroscino G., Lorkowski S., Lotufo P.A., Lozano R., Lucas T.C.D., Ma S., Macarayan E.R.K., Maddison E.R., Abd El Razek M.M., Majdan M., Majdzadeh R., Majeed A., Malekzadeh R., Malhotra R., Malta D.C., Manguerra H., Manyazewal T., Mapoma C.C., Marczak L.B., Markos D., Martinez-Raga J., Martins-Melo F.R., Martopullo I., McAlinden C., McGaughey M., McGrath J.J., Mehata S., Meier T., Meles K.G., Memiah P., Memish Z.A., Mengesha M.M., Mengistu D.T., Menota B.G., Mensah G.A., Meretoja A., Meretoja T.J., Millear A., Miller T.R., Minnig S., Mirarefn M., Mirrakhimov E.M., Misganaw A., Mishra S.R., Mohammad K.A., Mohammadi A., Mohammed S., Mokdad A.H., Mola G.L.D., Mollenkopf S.K., Molokhia M., Monasta L., Hernandez J.C.M., Montico M., Mooney M.D., Moradi-Lakeh M., Moraga P., Morawska L., Morrison S.D., Morozof C., Mountjoy-Venning C., Mruts K.B., Muller K., Murthy G.V.S., Musa K.I., Nachega J.B., Naheed A., Naldi L., Nangia V., Nascimento B.R., Nasher J.T., Natarajan G., Negoi I., Ngunjiri J.W., Nguyen C.T., Nguyen G., Nguyen M., Nguyen Q.L., Nguyen T.H., Nichols E., Ningrum D.N.A., Nong V.M., Noubiap J.J.N., Ogbo F.A., Oh I.-H., Okoro A., Olagunju A.T., Olsen H.E., Olusanya B.O., Olusanya J.O., Ong K., Opio J.N., Oren E., Ortiz A., Osman M., Ota E., Mahesh P.A., Pacella R.E., Pakhale S., Pana A., Panda B.K., Jonas S., Papachristou C., Park E.-K., Patten S.B., Patton G.C., Paudel D., Paulson K., Pereira D.M., Perez-Ruiz F., Perico N., Pervaiz A., Petzold M., Phillips M.R., Pigott D.M., Pinho C., Plass D., Pletcher M.A., Polinder S., Postma M.J., Pourmalek F., Purcell C., Qorbani M., Radfar A., Rafay A., Rahimi-Movaghar V., Rahman M., Ur Rahman M.H., Rai R.K., Ranabhat C.L., Rankin Z., Rao P.C., Rath G.K., Rawaf S., Ray S.E., Rehm J., Reiner R.C., Reitsma M.B., Remuzzi G., Rezaei S., Rezai M.S., Rokni M.B., Ronfani L., Roshandel G., Roth G.A., Rothenbacher D., Ruhago G.M., Rizwan S.A., Saadat S., Sachdev P.S., Sadat N., Safdarian M., Saf S., Safiri S., Sagar R., Sahathevan R., Salama J., Salamati P., Salomon J.A., Samy A.M., Sanabria J.R., Sanchez-Niño M.D., Santomauro D., Santos I.S., Milicevic M.M.S., Sartorius B., Satpathy M., Shahraz S., Schmidt M.I., Schneider I.J.C., Schulhofer-Wohl S., Schutte A.E., Schwebel D.C., Schwendicke F., Sepanlou S.G., Servan-Mori E.E., Shackelford K.A., Shaikh M.A., Shamsipour M., Shamsizadeh M., Islam S.M.S., Sharma J., Sharma R., She J., Sheikhbahaei S., Shey M., Shi P., Shields C., Shigematsu M., Shiri R., Shirude S., Shiue I., Shoman H., Shrime M.G., Sigfusdottir I.D., Silpakit N., Silva J.P., Singh A., Singh J.A., Skiadaresi E., Sligar A., Smith A., Smith D.L., Smith M., Sobaih B.H.A., Soneji S., Sorensen R.J.D., Soriano J.B., Sreeramareddy C.T., Srinivasan V., Stanaway J.D., Stathopoulou V., Steel N., Stein D.J., Steiner C., Steinke S., Stokes M.A., Strong M., Strub B., Subart M., Sufyan M.B., Sunguya B.F., Sur P.J., Swaminathan S., Sykes B.L., Tabarés-Seisdedos R., Tadakamadla S.K., Takahashi K., Takala J.S., Talongwa R.T., Tarawneh M.R., Tavakkoli M., Taveira N., Tegegne T.K., Tehrani-Banihashemi A., Temsah M.-H., Terkawi A.S., Thakur J.S., Thamsuwan O., Thankappan K.R., Thomas K.E., Thompson A.H., Thomson A.J., Thrift A.G., Tobe-Gai R., Topor-Madry R., Torre A., Tortajada M., Towbin J.A., Tran B.X., Troeger C., Truelsen T., Tsoi D., Tuzcu E.M., Tyrovolas S., Ukwaja K.N., Undurraga E.A., Updike R., Uthman O.A., Uzochukwu B.S.C., Van Boven J.F.M., Vasankari T., Venketasubramanian N., Violante F.S., Vlassov V.V., Vollset S.E., Vos T., Wakayo T., Wallin M.T., Wang Y.-P., Weiderpass E., Weintraub R.G., Weiss D.J., Werdecker A., Westerman R., Whetter B., Whiteford H.A., Wijeratne T., Wiysonge C.S., Woldeyes B.G., Wolfe C.D.A., Woodbrook R., Workicho A., Xavier D., Xiao Q., Xu G., Yaghoubi M., Yakob B., Yano Y., Yaseri M., Yimam H.H., Yonemoto N., Yoon S.-J., Yotebieng M., Younis M.Z., Zaidi Z., El Sayed Zaki M., Zegeye E.A., Zenebe Z.M., Zerfu T.A., Zhang A.L., Zhang X., Zipkin B., Zodpey S., Lopez A.D., Murray C.J.L., GBD 2016 Causes of Death Collaborators (2017)
      Background: Monitoring levels and trends in premature mortality is crucial to understanding how societies can address prominent sources of early death. The Global Burden of Disease 2016 Study (GBD 2016) provides a comprehensive ...

    • Hepatitis B, C and human immunodeficiency virus knowledge among the general greek population: results from the Hprolipsis nationwide survey 

      Kaskafetou S., Karakosta A., Sypsa V., Kalpourtzi N., Gavana M., Vantarakis A., Rachiotis G., Chlouverakis G., Trypsianis G., Voulgari P.V., Alamanos Y., Papatheodoridis G., Touloumi G., Hprolipsis study group (2022)
      BACKGROUND: Although several studies on hepatitis B (HBV), C (HCV) and human immunodeficiency virus (HIV) infection have been conducted in Greece, little is known on the knowledge level of the Greek population towards these ...

    • Hepatitis C virus survival curve analysis in naïve patients treated with PegInterferon α-2b plus ribavirin. A randomized controlled trial for induction with high doses of PegInterferon and predictability of sustained viral response from early virologic data 

      Mimidis, K.; Papadopoulos, V. P.; Elefsiniotis, I.; Koliouskas, D.; Ketikoglou, I.; Paraskevas, E.; Kanatakis, S.; Chrysagis, D.; Dalekos, G. N.; Tzathas, C.; Protopapas, A.; Gigi, E.; Tsianos, E.; Kartalis, G. (2006)
      Aim. To evaluate the significance of induction with high doses of pegylated interferon α-2b (Peg-IFNα-2b) and the predictability of sustained virologic response (SVR) in naïve patients with chronic hepatitis C. Methods. ...

    • Hepatocyte autotaxin expression promotes liver fibrosis and cancer 

      Kaffe E., Katsifa A., Xylourgidis N., Ninou I., Zannikou M., Harokopos V., Foka P., Dimitriadis A., Evangelou K., Moulas A.N., Georgopoulou U., Gorgoulis V.G., Dalekos G.N., Aidinis V. (2017)
      Autotaxin (ATX) is a secreted lysophospholipase D that catalyzes the production of lysophosphatidic acid (LPA), a pleiotropic growth-factor–like lysophospholipid. Increased ATX expression has been detected in various chronic ...

    • Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus-infected patients is associated with the possession of HLA B51 

      Bogdanos, D. P.; Lenzi, M.; Okamoto, M.; Rigopoulou, E. I.; Muratori, P.; Ma, Y.; Muratori, L.; Tsantoulas, D.; Mieli-Vergani, G.; Bianchi, F. B.; Vergani, D. (2004)
      Liver Kidney Microsomal autoantibody type 1(LKM1) directed to cytochrome P4502D6 (CYP2D6) characterises autoimmune hepatitis type-2 (AIH-2), but is also found in a proportion of chronic hepatitis C virus (HCV) infected ...

    • Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases 

      Georgiadou, S. P.; Zachou, K.; Rigopoulou, E.; Liaskos, C.; Mina, P.; Gerovasilis, F.; Makri, E.; Dalekos, G. N. (2004)
      Occult hepatitis B virus (HBV) infection has been reported in patients with chronic hepatitis C who are negative for HBV surface antigen (HBsAg). However, the significance of 'silent' HBV in hepatitis C virus (HCV) infection ...

    • Patients with haemoglobinopathies and chronic hepatitis C: A real difficult to treat population in 2016? 

      Zachou K., Arvaniti P., Gatselis N.K., Azariadis K., Papadamou G., Rigopoulou E., Dalekos G.N. (2017)
      Background & objectives: In the past, patients with haemoglobinopathies were at high risk of acquiring hepatitis C virus (HCV) due to multiple transfusions before HCV screening. In these patients, the coexistence of ...

    • PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis 

      Liu, H.; Norman, G. L.; Shums, Z.; Worman, H. J.; Krawitt, E. L.; Bizzaro, N.; Vergani, D.; Bogdanos, D. P.; Dalekos, G. N.; Milkiewicz, P.; Czaja, A. J.; Heathcote, E. J.; Hirschfield, G. M.; Tan, E. M.; Miyachi, K.; Bignotto, M.; Battezzati, P. M.; Lleo, A.; Leung, P. S.; Podda, M.; Gershwin, M. E.; Invernizzi, P. (2010)
      A dual isotype (IgG, IgA) enzyme-linked immunosorbent assay (ELISA) designed to provide enhanced detection of primary biliary cirrhosis (PBC)-specific autoantibodies against both major mitochondrial and nuclear antigens ...

    • Risk factors associated with HCV infection in semi-rural areas of central Greece 

      Gatselis, N. K.; Rigopoulou, E.; Stefos, A.; Kardasi, M.; Dalekos, G. N. (2007)
      Background: Hepatitis C virus (HCV) appears to be endemic in most parts of the world, but there is considerable geographic variation. In order to assess the geographic distribution of HCV in Thessaly, in central Greece, ...

    • The state of hepatitis B and C in the mediterranean and balkan countries: Report from a summit conference 

      Hatzakis, A.; Van Damme, P.; Alcorn, K.; Gore, C.; Benazzouz, M.; Berkane, S.; Buti, M.; Carballo, M.; Cortes Martins, H.; Deuffic-Burban, S.; Dominguez, A.; Donoghoe, M.; Elzouki, A. N.; Ben-Alaya Bouafif, N.; Esmat, G.; Esteban, R.; Fabri, M.; Fenton, K.; Goldberg, D.; Goulis, I.; Hadjichristodoulou, T.; Hatzigeorgiou, T.; Hamouda, O.; Hasurdjiev, S.; Hughes, S.; Kautz, A.; Malik, M.; Manolakopoulos, S.; Matičič, M.; Papatheodoridis, G.; Peck, R.; Peterle, A.; Potamitis, G.; Prati, D.; Roudot-Thoraval, F.; Reic, T.; Sharara, A.; Shennak, M.; Shiha, G.; Shouval, D.; Sočan, M.; Thomas, H.; Thursz, M.; Tosti, M.; Trépo, C.; Vince, A.; Vounou, E.; Wiessing, L.; Manns, M. (2013)
      The burden of disease due to chronic viral hepatitis constitutes a global threat. In many Balkan and Mediterranean countries, the disease burden due to viral hepatitis remains largely unrecognized, including in high-risk ...

    • Telomerase reverse transcriptase mRNA expression in peripheral lymphocytes of patients with chronic HBV and HCV infections 

      Satra, M.; Dalekos, G. N.; Kollia, P.; Vamvakopoulos, N.; Tsezou, A. (2005)
      Telomerase activity is present at low levels in peripheral lymphocytes (PL) and is upregulated upon activation, possibly protecting PL from telomere shortening. As decreased telomere length is considered a sign of cellular ...